Fred G Weiss
CIK 1081534 · last filed 2021-09-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
WPI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PRINCETON, NJ 08536
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RVL Pharmaceuticals plc (OSMT) Delisted | Director | 118,466 | $1.11 | $131.5K | $0 | 8 | 2021-09-03 |
| Allergan plc (AGN) Delisted | Director | 29,675 | — | — | $0 | 5 | 2018-05-04 |
| ACT | Director | 24,868 | $46.95 | $1.17M | $0 | 2 | 2015-06-08 |
| Actavis, Inc. (WPI) Delisted | Director | 55,398 | — | — | -$3.89M | 8 | 2012-07-31 |
Recent Filings · Page 2 of 3
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-08-09 | Allergan plc (AGN) Delisted | Grant (A) | +201 | $49.9K | EDGAR |
| 2016-05-09 | Allergan plc (AGN) Delisted | Grant (A) | +1,188 | $249.9K | EDGAR |
| 2015-06-30 | Allergan plc (AGN) Delisted | Mixed | +277 | $83.1K | EDGAR |
| 2015-06-08 | ACT | Mixed | +277 | $83.1K | EDGAR |
| 2013-11-18 | — | Sell (S) | −3,000 | -$492.4K | |
| 2013-10-03 | — | Grant (A) | +27,275 | $0 | |
| 2013-10-02 | ACT | Disp (D) | −27,275 | $0 | EDGAR |
| 2013-05-14 | — | Grant (A) | +1,877 | $0 | |
| 2012-07-31 | Actavis, Inc. (WPI) Delisted | Mixed | — | -$1.27M | EDGAR |
| 2012-05-14 | Actavis, Inc. (WPI) Delisted | Grant (A) | +2,887 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.